Company Description
Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers.
Our novel prostate cancer genomic testing products, Decipher Biopsy and Decipher RP, provide valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy.
Our differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to help physicians improve therapy selection and accelerate adoption of new therapies into the standard of care.
Collectively, our genomic tests have been used by more than 3,200 urologists and radiation oncologists, and at all 28 National Comprehensive Cancer Network, or NCCN, centers in the United States.
Our prostate cancer products are covered by Medicare in nine clinical indications, representing the entire known spectrum of localized, regional and biochemically recurrent prostate cancer.
Six of our clinical indications received Medicare coverage in 2020.
| Country | United States |
| Founded | 2008 |
| Industry | Medical Devices |
| Sector | Biotechnology |
| Employees | 95 |
| CEO | Tina S. Nova, Ph.D. |
Contact Details
Address: 6925 Lusk Boulevard, Suite 200 San Diego, CA 92121 United States | |
| Phone | (888) 975-4540 |
| Website | decipherbio.com |
Stock Details
| Ticker Symbol | DECI |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001668069 |
| Employer ID | 98-1205079 |
| SIC Code | 3841 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 19, 2021 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 4, 2020 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 27, 2020 | D | Notice of Exempt Offering of Securities |
| Mar 16, 2020 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 15, 2020 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 14, 2019 | DRS | [Cover] Draft Registration Statement |
| Apr 11, 2019 | D | Notice of Exempt Offering of Securities |
| Jan 18, 2019 | D | Notice of Exempt Offering of Securities |
| Oct 9, 2018 | D | Notice of Exempt Offering of Securities |
| Sep 25, 2018 | D | Notice of Exempt Offering of Securities |